The race in biosimilar development is becoming more competitive – and crucial – by the day. The National Center for Biotechnology Information estimates that $100 billion (USD) in biologic drug sales will lose patent protection by 2020.

This projection, combined with global public healthcare budget cuts and advances in biologic manufacturing technology, is creating an intensely competitive marketplace.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Biosimilar drug development presents a host of challenges – constantly evolving global regulatory pathways, and the necessary optimisation of clinical development plans in order to not only gain approval, but to also achieve the ultimate goal of gaining market share.

This article focuses on one specific aspect of biosimilar development: How do we access the reference drug?

 

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

*To finish reading this excellent whitepaper, visit Myoderm’s storefront page here

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now